KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $120.0 million.

  • Abbott Laboratories' Share-based Compensation rose 256.41% to $120.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $662.0 million, marking a year-over-year decrease of 207.1%. This contributed to the annual value of $673.0 million for FY2024, which is 450.31% up from last year.
  • According to the latest figures from Q3 2025, Abbott Laboratories' Share-based Compensation is $120.0 million, which was up 256.41% from $142.0 million recorded in Q2 2025.
  • Over the past 5 years, Abbott Laboratories' Share-based Compensation peaked at $305.0 million during Q1 2022, and registered a low of $106.0 million during Q4 2021.
  • Its 5-year average for Share-based Compensation is $168.1 million, with a median of $132.0 million in 2021.
  • In the last 5 years, Abbott Laboratories' Share-based Compensation surged by 2360.52% in 2021 and then tumbled by 786.89% in 2023.
  • Quarter analysis of 5 years shows Abbott Laboratories' Share-based Compensation stood at $106.0 million in 2021, then grew by 8.49% to $115.0 million in 2022, then fell by 0.87% to $114.0 million in 2023, then fell by 2.63% to $111.0 million in 2024, then rose by 8.11% to $120.0 million in 2025.
  • Its Share-based Compensation stands at $120.0 million for Q3 2025, versus $142.0 million for Q2 2025 and $289.0 million for Q1 2025.